Teva
19 federal recalls on file. We monitor every CPSC, FDA, USDA, and NHTSA notice for Teva and translate it into plain English — free weekly digest, optional same-day alerts.
- 2026-04-29FDA-DrugNot Yet ClassifiedReturn Teva Claravis isotretinoin to your pharmacy
Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
- 2026-04-15FDA-DrugClass IIStop using recalled Teva Clonidine patches
CGMP Deviations: use of an unapproved raw material
- 2026-04-15FDA-DrugClass IICheck your Clonidine patch lot numbers
CGMP Deviations: use of an unapproved raw material
- 2026-04-15FDA-DrugClass IIStop using recalled Teva Clonidine patches
CGMP Deviations: use of an unapproved raw material
- 2026-04-15FDA-DrugClass IIStop using Teva Isotretinoin 40 mg capsules
Superpotent and Subpotent
- 2026-04-15FDA-DrugClass IIStop using Teva Isotretinoin 30 mg capsules
Superpotent and Subpotent
- 2026-04-01FDA-DrugClass IIStop using recalled Teva Octreotide Acetate injections
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- 2026-04-01FDA-DrugClass IIStop using Teva Octreotide Acetate injections
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- 2026-04-01FDA-DrugClass IIStop using Teva Octreotide Acetate injection
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- 2026-03-11FDA-DrugClass IIStop using Teva metoprolol succinate 200 mg tablets
Failed Dissolution Specifications
- 2026-03-11FDA-DrugClass IIStop taking Teva Metoprolol Succinate tablets
Failed Dissolution Specifications
- 2026-03-11FDA-DrugClass IIStop using Teva Metoprolol Succinate 50 mg tablets
Failed Dissolution Specifications
- 2026-03-11FDA-DrugClass IIStop using Teva Metoprolol Succinate tablets
Failed Dissolution Specifications
- 2025-12-10FDA-DrugClass IIICarton label: Testosterone Gel 1%, 2.5 grams per unit dose, CIII, 30 unit-dose packets, Rx only, Manufactured by: Actavis Laboratories, Inc, Salt Lake City, UT 84108, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, NDC 0591-3216-30. Packet label: Testosterone Gel 1%, contains 2.5 grams, For topical use only, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054,NDC: 0591-3216-17.
Defective Container - A defect in the side-seal which allows leakage of product.
- 2025-11-12FDA-DrugClass IIAmoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.
Subpotent drug; Clavulanate Potassium component
- 2025-11-05FDA-DrugClass IIPrazosin Hydrochloride, Capsules, USP, 5 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093-4069-01, b) 250 Capsules, NDC 0093-4069-52, c) 500 Capsules, NDC 0093-4069-05
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
- 2025-11-05FDA-DrugClass IIPrazosin Hydrochloride, Capsules, USP, 2 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093-4068-01, b) 1000 Capsules, NDC 0093-4068-10
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
- 2025-11-05FDA-DrugClass IIPrazosin Hydrochloride, Capsules, USP, 1 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093-4067-01, b) 1000 Capsules, NDC 0093-4067-10
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
- 2018-10-10FDA-DrugClass IIStop using Teva Clozapine 12.5 mg tablets
Failed Disintegration Specifications: Out-of-specification disintegration test result obtained during routine stability testing.
Get notified about new Teva recalls
Free weekly digest. We email when a new federal recall affects Teva or anything else in your household.
Get the Sunday Brief